Skip to Content
Merck
CN
  • Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues.

Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues.

Nature communications (2017-12-01)
Ilya Y Shadrin, Brian W Allen, Ying Qian, Christopher P Jackman, Aaron L Carlson, Mark E Juhas, Nenad Bursac
ABSTRACT

Despite increased use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for drug development and disease modeling studies, methods to generate large, functional heart tissues for human therapy are lacking. Here we present a "Cardiopatch" platform for 3D culture and maturation of hiPSC-CMs that after 5 weeks of differentiation show robust electromechanical coupling, consistent H-zones, I-bands, and evidence for T-tubules and M-bands. Cardiopatch maturation markers and functional output increase during culture, approaching values of adult myocardium. Cardiopatches can be scaled up to clinically relevant dimensions, while preserving spatially uniform properties with high conduction velocities and contractile stresses. Within window chambers in nude mice, cardiopatches undergo vascularization by host vessels and continue to fire Ca

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thrombin from bovine plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
Sigma-Aldrich
Poly(dimethylsiloxane), viscosity 1.0 cSt (25 °C)
Sigma-Aldrich
Fibrinogen from human plasma, 35-65% protein (≥90% of protein is clottable).